News
CAPITAL RAISING UPDATE - SHARE PURCHASE PLAN
11-Sep-2009Adelaide, Australia: Bionomics Limited (ASX:BNO) as announced to the market on 7 September 2009 Bionomics is undertaking a Share Purchase Plan (SPP). Bionomics will shortly be sending documentation to eligible shareholders offering the opportunity to participate in the SPP at the same issue price as the placement to Institutional Investors which was also announced on 7 September 2009. As previously announced the Company has in place an underwriting agreement with LINWAR Securities Pty Ltd for $2.2 million which is to be raised in the SPP.
Key points relating to the SPP are:
Offer details
Issue Price $0.24 per share
Application Amounts $5,000 (20,833 shares) or $15,000 (62,500 shares)
Key dates
| Record Date: 14 September 2009 | Date for determining Eligible Shareholders |
| Opening and Mailing Date: 16 September 2009 | Share Purchase Plan opens and documentation mailed to eligible shareholders |
| Closing Date: 2 October 2009 | Share Purchase Plan closes at 5.00pm (Adelaide time) on this Date |
| Allotment Date: 12 October 2009 | Shares to be issued under Share Purchase Plan are allotted |
Despatch Date: 15 October 2009 | Confirmation of transaction despatched to shareholders (Allotment Notice) |
* Dates are indicative only and Bionomics retains the right to vary these dates without advance notice.
FOR FURTHER INFORMATION PLEASE CONTACT:
Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au
About Bionomics Limited
Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.
For more information about Bionomics, visit www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of BNC105, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
